Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.51 |
| ▸ | PGR | P06401 | 15/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12904844 | 0.91 | PGR (0.52) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL12904838 | 0.91 | AR (0.52) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL12904841 | 0.88 | AR (0.54) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL12904960 | 0.88 | AR (0.67) | ARPGRNR3C2 | |
| SCHEMBL12904874 | 0.88 | AR (0.67) | ARPGRNR3C2 | |
| SCHEMBL12904815 | 0.88 | AR (0.67) | ARPGRNR3C2 | |
| SCHEMBL12904802 | 0.87 | AR (0.50) | ARPGRNR3C2PDK1PDK2 | |
| SCHEMBL15417492 | 0.87 | AR (0.54) | ARPGRNR3C2 | |
| SCHEMBL12904833 | 0.87 | NR1I2 (0.53) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL12904854 | 0.85 | PGR (0.41) | ARPGRNR3C2NR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623850-B2 | 15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110003779-A1 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003779-A1 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | CYP19A1, NR5A1, SRD5A1 | AR 19/4885PGR 9/4885NR3C2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.